Brain metastases arising from prostate cancer are exceedingly rare and typically occur late in the course of the disease. Most patients have widespread metastatic disease before developing brain metastases from prostate cancer. We report the case of a 67-year-old male with prostate cancer presenting with an isolated symptomatic brain metastasis. Aggressive treatment of the metastatic site included tumor resection and adjuvant stereotactic radiation treatment (RT) to the surgical bed, resulting in a favorable outcome.
Introduction
Prostate cancer commonly metastasizes to the pelvic lymph nodes, axial skeleton, and lungs (1, 2) . Brain metastases from prostate cancer are rare and are usually discovered post-mortem. These metastases typically only occur in the context of widespread metastatic disease. It is even more uncommon to have the brain as the sole site of metastatic prostate cancer. We present the case of a 67-year-old male who presented with recurrence of prostate cancer with a solitary brain metastasis, treated with tumor resection and adjuvant stereotactic radiation treatment (RT) to the surgical bed.
Case presentation
A 67-year-old male was initially diagnosed with prostate cancer in 2008, presenting with a prostate specific antigen (PSA) of 53.13 ng/dL. Clinical exam and biopsy revealed a Gleason 8 (4+4), T3a prostate cancer. Staging with CT scans and bone scan did not show any evidence of systemic disease.
The patient received RT in a two phase plan to his pelvic lymph nodes and prostate. The pelvis received a dose of 46 Gy in 23 fractions in phase 1, and a total dose of 76 Gy in 38 fractions by the end of phase 2. Androgen deprivation therapy (ADT) was subsequently initiated for a period of three years. Approximately one year after initiation of ADT, his PSA was undetectable. The patient remained on ADT until 2012, and showed no evidence of recurrence until 2014, when he presented with symptoms of dizziness, mild dysphagia and imbalance. Following a suspicious fall in his urologist's office, he was referred to the Emergency Department where an MRI of his brain showed a heterogeneous, multi-lobulated intra-axial lesion in the left frontal lobe with rim enhancement and surrounding edema ( Figure 1) . He was referred to a neurosurgeon and had repeat staging which showed no evidence of extracranial disease. His PSA two years following termination of ADT rose from an undetectable <0.2 to 3.7 ng/dL. A left temporal craniotomy and gross total resection of the tumor was performed. The final pathologic diagnosis confirmed prostate cancer, staining positive for PSA. The patient experienced a complication-free postoperative recovery with no neurological deficits. Tumor resection was followed by stereotactic radiation therapy to the surgical cavity with a dose of 30 Gy in 5 fractions ( Figure 2) . ADT was subsequently re-initiated, resulting in the patient's PSA returning to an undetectable level and remaining undetectable with no evidence of disease 17 months post-radiotherapy. Follow-up MRI imaging of his head confirmed no residual or recurrent disease (Figure 3 ).
Discussion
The ante-mortem diagnosis of a solitary metastasis to the brain from prostate cancer is exceedingly rare; our review of the literature identified 16 previously-reported cases in the literature over the past 25 years (3-13) ( Table 1 ). Survival in these cases generally mostly ranged between 2 to 20 months, with some patients still alive at the time of reporting. In one case, a patient presenting with a right cerebellar infarct following transurethral resection of the prostate three months earlier was reported to remain alive and symptom-free 5 years post-operatively following suboccipital craniotomy with excision of the mass, which was noted to be moderately differentiated adenocarcinoma, and whole brain radiation therapy (WBRT) and radiotherapy to the posterior fossa (4) . In another case, a patient with pathologic Gleason 9 (4+5) prostate adenocarcinoma was reported to remain alive 5 years post-treatment without signs of recurring disease (11) . For decades, surgical resection with adjuvant WBRT has been the standard of care for solitary metastases in the brain. This combined therapy strategy has been evaluated in randomized studies and found to significantly reduce the risk of recurrence when compared with surgical resection or WBRT alone (14) (15) (16) (17) . These studies, however, did not include any patients with prostate cancer brain metastases patients. Due to concerns of WBRT-related neurotoxicity and the risk of neurocognitive side effects, the application of high dose radiation to the postoperative surgical bed through stereotactic radiosurgery has been increasing in clinical practice (18) . Stereotactic radiosurgery alone following surgical resection of a brain metastasis has the potential to limit long-term neurocognitive side effects and improve local control as compared to WBRT (19, 20) .
The risk of distant brain recurrence in patients with brain metastases from prostate cancer is unknown. The potential for WBRT to decrease distant brain recurrence as compared to cavity stereotactic radiosurgery is, therefore, also unknown. In this case, given that there was only one site of disease, it was felt to be reasonable to forego WBRT and monitor with brain imaging on a three-month basis. The approach has appeared effective thus far, with no evidence of new or recurrent disease in the brain at the time of report.
Conclusions
Metastatic disease exclusive to the brain in prostate cancer patients remains extremely infrequent. This unique case of a 67-year-old male with a solitary brain metastasis arising from prostate cancer demonstrates that aggressive treatment with tumor resection and adjuvant stereotactic RT to the surgical bed without WBRT may be optimal in the management of such patients.
